Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with st-elevation myocardial infarction a randomized clinical trial

JAMA Cardiology

Volumn 3, Issue 5, 2018, Pages 391-399

  Berwanger, Otavio ^a   Nicolau, Jose C ^b   Carvalho, Antonio C ^c   Jiang, Lixin ^d   Goodman, Shaun G ^e   Nicholls, Stephen J ^f   Parkhomenko, Alexander ^g   Averkov, Oleg ^h   Tajer, Carlos ⁱ   Malaga, Germán ^j   Saraiva, Jose F K ^k   Fonseca, Francisco A ^c   De Luca, Fábio A ^l   Guimaraes, Helio P ^a   De Barros E Silva, Pedro G M ^a   Damiani, Lucas P ^a   Paisani, Denise M ^a   Lasagno, Camila M R ^a   Candido, Carolina T ^a   Valeis, Nanci ^a   Moia, Diogo D F ^a   Piegas, Leopoldo S ^a   Granger, Christopher B ^m   White, Harvey D ⁿ   Lopes, Renato D ^m   more..

^a Research Institute   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d FUWAI HOSPITAL   (China)

^e CANADIAN HEART RESEARCH CENTRE   (Canada)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^h PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

ⁱ Hospital de Alta Complejidad El Cruce ^*  (Argentina)

^j UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^k Hospital e Maternidade Celso Pierro   (Brazil)

^l Grajau General Hospital   (Brazil)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; FIBRINOLYTIC AGENT;

ADULT; AGED; ARGENTINA; ARTERY THROMBOSIS; ARTICLE; AUSTRALIA; BLEEDING; BRAIN HEMORRHAGE; BRAZIL; CANADA; CEREBROVASCULAR ACCIDENT; CHINA; COLOMBIA; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; OPEN STUDY; PATIENT COMPLIANCE; PERU; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RUSSIAN FEDERATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY DELAY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UKRAINE; CLINICAL TRIAL; COMPARATIVE STUDY;

AGED; CLOPIDOGREL; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TICAGRELOR;

EID: 85048300372     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2018.0612     Document Type: Article

References (19)

1. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4): E362-e425.
2. Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acutemyocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177.
3. Vora AN, Holmes DN, Rokos I, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevationmyocardial infarction care: A report from the US National Cardiovascular Data Registry. JAMA Intern Med. 2015;175(2):207-215.
4. Gandhi S, Zile B, Tan MK, et al; Canadian ACS Reflective Group. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol. 2014;30(12): 1725-1731.
5. Chen ZM, Jiang LX, Chen YP, et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet. 2005;366(9497): 1607-1621.
6. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352 (12): 1179-1189.
7. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27 (9): 1038-1047.
8. Husted S, van Giezen JJJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259-274.
9. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
10. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: Rationale and Design of the TicagRElor in pAtients with ST elevationmyocardial infarction treated with Thrombolysis (TREAT) trial. Am Heart J. 2018.
11. Steg PG, James S, Harrington RA, et al; PLATO Study Group. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131-2141.
12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23): 2736-2747.
13. Montalescot G, van't Hof AW, Lapostolle F, et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevationmyocardial infarction. N Engl J Med. 2014;371(11):1016-1027.
14. Van De Werf F, Adgey J, Ardissino D, et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acutemyocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet. 1999; 354 (9180): 716-722.
15. Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acutemyocardial infarction. N Engl J Med. 2008;358(21):2218-2230.
16. R Core Team. R: A language and environment for statistical computing. http://www.R-project.org/. Published 2017. Accessed January 1, 2018.
17. Dehghani P, Lavoie A, Lavi S, et al. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-Treated STEMI patients undergoing early PCI. Am Heart J. 2017;192:105-112.
18. Guimarães LFC, Généreux P, Silveira D, et al. P2Y12receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial. Int J Cardiol. 2017; 230: 204-208.
19. Alexopoulos D, Perperis A, Koniari I, et al. Ticagrelor versus high dose clopidogrel in ST-segment elevationmyocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis. 2015;40(3): 261-267.